Anika Therapeutics | ANIK - Ebitda


Anika Therapeutics reported $4.54M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Abbott USD 3.27B 178M Dec/2025
Agenus USD -10.11M 19.02M Mar/2025
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -314.19M 31.48M Dec/2025
Integra LifeSciences USD 76.18M 28.03M Mar/2026
Intrexon USD -24.7M 2.92M Jun/2024
J&J USD 7.19B 2.32B Dec/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD 150.32M 129.42M Sep/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Merit Medical Systems USD 97.23M 17.69M Dec/2025
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Sanofi EUR 3.31B 3.65B Mar/2026
Smith & Nephew USD 796M 139M Dec/2025
Stryker USD 1.57B 618M Mar/2026
Surmodics USD 3.43M 1.9M Jun/2025
Veracyte USD 42.31M 2.58M Dec/2025
Xencor USD -51.05M 55.28M Dec/2025
Zimmer Biomet Holdings USD 759M 120.8M Dec/2025